PEMBROLIZUMAB-COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER IN REAL-WORLD PRACTICE

Abstract

Pembrolizumab is a programmed cell death protein 1 (PD-1) inhibitor approved for metastatic non-small cell lung cancer (NSCLC) combined with chemotherapy, regardless of tumor programmed cell death protein ligand-1 (PD-L1) production. In real-world clinical practice, patients can clinically benefit from immunochemotherapy regardless of the expression of PD-L1 and the histological type.